OUR STORY
After coming together though and winning the Perth Biodesign program in 2019, Nikhilesh Bappoo PhD, Nicholas Buckley BSc & Dr Katherine Arenson FACEM have prioritizing the needs of patients, clinicians and providers to deliver their award winning solution.
VeinTech are positioned to solve a long accepted but unacceptable pain-point in healthcare: the high rate of first pass cannulation failure rates. In less than 4 years since incorporation, the founding team delivered working clinical prototypes with positive safety and performance data in healthy humans to accelerate towards early manufacturing, clinical translation and commercialization.
Our team has been extremely efficient investing every dollar into value inflecting assets and are now finalizing our MVP for our first regulatory submission, whilst incorporating feedback from the numerous feasibility studies completed. If you'd like to find out more about the next chapter for VeinTech, please reach out.
_edited.jpg)
Timeline
Seed Funding
Need Identification
-
Perth Biodesign winners
-
Clinical Need validation
Technical Feasibility
-
Awarded MTP connect grant
-
Pre-seed funding from leading research institutions and Angel Investors
-
Technical feasibility proven
-
Won WA Innovator of the Year (Great for the State) & MedTech Actuator Origin (APAC)
-
Advisory Board established
-
Seed round + multiple grants
-
Clinical prototype
-
Human data
-
Second patent
-
Team of 9+ growing
-
US chairman and Clinical KOL
-
FDA Pre-submission
-
Three usability studies
2019
2020
2021
Company Formation
-
Incorporation
-
First Government grant
2022
2023
Pre-Seed Milestones
-
Proof of concept
-
First Provisional Patent
-
Full time founders and first employee
-
Clinical partnerships
2021 WINNER
2019 WINNER
2021 WINNER